drugset / Trial / NCT03225352

A Study to Assess Disintegration of the New Aspirin Disintegrating Tablets

NCT03225352

Phase 1 Completed 12 enrolled Bayer
RandomizedCrossoverOpen-labelOther

Summary

The aim of this study is to assess disintegration of the new Aspirin disintegrating tablets

Timeline

Start
2017-08-07
Primary completion
2017-10-07
Completion
2017-10-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Aspirin Small molecule 500 mg
Subject Aspirin Small molecule 1000 mg
Subject Ibuprofen Small molecule 400 mg

Indications

No indication recorded.